NASDAQ:HILS Hillstream BioPharma (HILS) Stock Price, News & Analysis $1.44 -0.12 (-7.69%) As of 05/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Hillstream BioPharma Stock (NASDAQ:HILS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hillstream BioPharma alerts:Sign Up Key Stats Today's Range$1.43▼$1.5750-Day Range$1.06▼$1.7352-Week Range$0.19▼$2.65Volume28,791 shsAverage Volume1.39 million shsMarket Capitalization$25.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Read More… Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HILS Stock News HeadlinesHill & Smith PLC HILSApril 17, 2024 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPOctober 31, 2023 | morningstar.comThe Trade Deal Is a DistractionTrump's trade deal with China made headlines. Stocks popped. Politicians took a victory lap. But here's the truth no one's telling you: Nothing has changed.May 14, 2025 | Lear Capital (Ad)Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 22, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 21, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 11, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13September 8, 2023 | finance.yahoo.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 30, 2023 | benzinga.comSee More Headlines HILS Stock Analysis - Frequently Asked Questions How have HILS shares performed this year? Hillstream BioPharma's stock was trading at $2.06 at the beginning of 2025. Since then, HILS shares have decreased by 30.1% and is now trading at $1.44. View the best growth stocks for 2025 here. When did Hillstream BioPharma IPO? Hillstream BioPharma (HILS) raised $21 million in an initial public offering (IPO) on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share. How do I buy shares of Hillstream BioPharma? Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hillstream BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hillstream BioPharma investors own include Absci (ABSI), Luminar Technologies (LAZR), Agnico Eagle Mines (AEM), Amprius Technologies (AMPX), Atai Life Sciences (ATAI), BioTelemetry (BEAT) and BioSig Technologies (BSGM). Company Calendar Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HILS CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-188.44% Return on Assets-149.61% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.15Miscellaneous Outstanding Shares17,603,000Free Float12,280,000Market Cap$26.58 million OptionableNot Optionable Beta3.08 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:HILS) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | SponsoredBITCOIN Liquidity pools are the backbone of crypto—and right now, they’re exploding with activity. By providing liqui...Awesomely, LLC | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.